Post

New research · Internal Medicine
Journal of thrombosis and haemostasis : JTH · 3h
Case-controlJournal of thrombosis and haemostasis : JTH · 2026

Plasma levels of adiponectin and risk of future incident venous thromboembolism.

Asbjørn L Onsaker, Astrid van Hylckama Vlieg, Thor Ueland … Vânia M Morelli
Read paper
Internal MedicineCase-control

Higher plasma adiponectin levels associated with lower risk of first venous thromboembolism

Plasma levels of adiponectin and risk of future incident venous thromboembolism.

Asbjørn L Onsaker … Vânia M Morelli
Journal of thrombosis and haemostasis : JTH · 2026
Background

Adiponectin, a hormone-like protein primarily secreted by adipocytes, is typically decreased in obesity.

Purpose

To investigate the association between plasma adiponectin levels and risk of future first lifetime VTE.

Methods

A population-based nested case-control study, including 381 VTE cases and 772 age-and sex-matched controls, was derived from the Tromsø4 survey (1994/95-2007).

n = 381 VTE cases and 772 age-and
Results

high adiponectin, lower future clot risk

OR 0.69 (95% CI 0.48 to 0.99)
null 1
0.48
0.99
CI excludes the null - significant
More results

Q1 (reference) in age- and sex-adjusted analysis for the entire study period.

Q1.

The additional adjustment for body mass index and C-reactive protein had minor impact on risk estimates.

“
Conclusion

Our results suggest that high plasma adiponectin levels are associated with decreased risk of future first lifetime VTE, particularly shortly after cohort inclusion, and that adiponectin might play a role in the pathogenesis of VTE.

Read paper
0 comments

No comments yet. Be the first.

Related papers

LatestFoundational
Cohort Study
13.5%
Central retinal artery peak blood-flow speed was 13.5% lower in diabetic patients.
Cohort Study
4.5 minutes
Each visual-field test averaged 4.5 minutes per eye.
Review
46.7%
nearly half of thyroid patients had Graves' disease, the most common overactive-thyroid condition
Cross-sectional
MYR 88,346.12
Average annual out-of-pocket expenditure for patients with cancer in Malaysia.
Case-control
5.4% Reduction in Odds of Neuropathy
each rise in zinc levels lowers the chance of nerve damage
Cross-sectional
SIR 9.93
risk climbs sharply when relatives cluster and clotting starts young
Cohort Study
67.8%
one-year survival was far worse than the intermediate-risk group's, roughly one in three died
Systematic Review
“Current evidence does not support universal thromboprophylaxis following ACLR.”